Updated Briefing and Discovery Schedule for CITGO Sale Hearing
Article content
PEMBROKE, Bermuda — Gold Reserve Ltd. (TSX.V: GRZ) (OTCQX: GDRZF) (' Gold Reserve ' or the ' Company ') announces that the U.S. District Court for the District of Delaware (the ' Court ') issued an order adopting the following revised schedule for briefing and discovery deadlines proposed by the Special Master given the expiration of the Topping Period on June 18, 2025 and rescheduled start date for the Sale Hearing to August 18, 2025, as previously announced here.
Article content
Event
Deadline
Deadline for the Special Master to submit his Final Recommendation
July 2
Deadline to serve written discovery on the party (or parties) whose bid is selected as the Final Recommendation
July 7
Opening expert reports due
July 7
Deadline for the filing of any objections to the Special Master's Final Recommendation
July 9
Deadline for any Competing Objector to disclose its own bid materials (such materials to be commensurate with those disclosed by the Special Master of the recommended bid)
July 9
Deadline to serve written discovery on a Competing Objector
July 11
Deadline to serve responses and objections for discovery requests served after the Final Recommendation
July 15
Deadline to meet and confer regarding the scope of discovery to be produced in response to discovery requests served after submission of the Final Recommendation
July 16
Deadline to serve witness disclosures pursuant to FRCP 26(a)(3)
July 18
Deadline to notice witness depositions
July 21
Deadline to serve responsive expert reports
July 21
Deadline to complete document productions in response to discovery requests served before the submission of the Final Recommendation and substantially complete document productions in response to discovery requests served after the submission of the Final Recommendation
July 22
Deadline to serve reply expert reports, if any
July 25
Conclusion of the discovery period
July 31
Deadline for the filing of responses to objections to the Special Master's Final Recommendation
August 1
Deadline for the filing of replies regarding any objections to the Special Master's Final Recommendation
August 8
Deadline for the filing of sur-replies to replies regarding any objections to the Special Master's Final Recommendation (only to the extent new arguments are raised in reply briefing)
August 12
Deadline for the Special Master to submit Joint Status Report
August 13
Deadline to disclose exhibits pursuant to FRCP 26(a)(3)
August 13
Deadline to serve objections to FRCP 26(a)(3) exhibit disclosures
August 15
Commencement of the Sale Hearing
August 18
Article content
Article content
A copy of the Court's complete order can be found here.
Article content
A complete description of the Delaware sale proceedings can be found on the Public Access to Court Electronic Records system in Crystallex International Corporation v. Bolivarian Republic of Venezuela, 1:17-mc-00151-LPS (D. Del.) and its related proceedings.
Article content
This release contains 'forward-looking statements' within the meaning of applicable U.S. federal securities laws and 'forward-looking information' within the meaning of applicable Canadian provincial and territorial securities laws and state Gold Reserve's and its management's intentions, hopes, beliefs, expectations or predictions for the future. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management at this time, are inherently subject to significant business, economic and competitive uncertainties and contingencies. They are frequently characterized by words such as 'anticipates', 'plan', 'continue', 'expect', 'project', 'intend', 'believe', 'anticipate', 'estimate', 'may', 'will', 'potential', 'proposed', 'positioned' and other similar words, or statements that certain events or conditions 'may' or 'will' occur. Forward-looking statements contained in this press release include, but are not limited to, statements relating to any bid submitted by the Company for the purchase of the PDVH shares (the 'Bid').
Article content
We caution that such forward-looking statements involve known and unknown risks, uncertainties and other risks that may cause the actual events, outcomes or results of Gold Reserve to be materially different from our estimated outcomes, results, performance, or achievements expressed or implied by those forward-looking statements, including but not limited to: the discretion of the Special Master to consider the Bid, to enter into any discussions or negotiation with respect thereto and that the Special Master may reject the Bid at any time; the Special Master may choose not to recommend a Base Bid or Final Bid to the Court; the failure of the Company to negotiate the Bid, including as a result of failing to obtain sufficient equity and/or debt financing; that Bid submitted by the Company will not be selected as the 'Base Bid' or the 'Final Recommend Bid' under the Bidding Procedures, and if selected may not close due to the Sale Process not being completed, including as a result of not obtaining necessary regulatory approval to close on the purchase of the PDVH shares, including but not limited to any necessary approvals from the U.S. Office of Foreign Asset Control ('OFAC'), the U.S. Committee on Foreign Investment in the United States, the U.S. Federal Trade Commission or the TSX Venture Exchange; failure of the Company or any other party to obtain any required shareholders approvals for, or satisfy other conditions to effect, any transaction resulting from the Bid; that the Company forfeit any cash amount deposit made due to failing to complete the Bid or otherwise; that the making of the Bid or any transaction resulting therefrom may involve unexpected costs, liabilities or delays; that, prior to or as a result of the completion of any transaction contemplated by the Bid, the business of the Company may experience significant disruptions due to transaction related uncertainty, industry conditions, tariff wars or other factors; the ability to enforce the writ of attachment granted to the Company; the timing set for various reports and/or other matters with respect to the Sale Process may not be met; the ability of the Company to otherwise participate in the Sale Process (and related costs associated therewith); the amount, if any, of proceeds associated with the Sale Process; the competing claims of other creditors of Venezuela, PDVSA and the Company, including any interest on such creditors' judgements and any priority afforded thereto; uncertainties with respect to possible settlements between Venezuela and other creditors and the impact of any such settlements on the amount of funds that may be available under the Sale Process; and the proceeds from the Sale Process may not be sufficient to satisfy the amounts outstanding under the Company's September 2014 arbitral award and/or corresponding November 15, 2015 U.S. judgement in full; and the ramifications of bankruptcy with respect to the Sale Process and/or the Company's claims, including as a result of the priority of other claims. This list is not exhaustive of the factors that may affect any of the Company's forward-looking statements. For a more detailed discussion of the risk factors affecting the Company's business, see the Company's Management's Discussion & Analysis for the year ended December 31, 2024 and other reports that have been filed on SEDAR+ and are available under the Company's profile at www.sedarplus.ca.
Article content
Investors are cautioned not to put undue reliance on forward-looking statements. All subsequent written and oral forward-looking statements attributable to Gold Reserve or persons acting on its behalf are expressly qualified in their entirety by this notice. Gold Reserve disclaims any intent or obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of assumptions or factors, whether as a result of new information, future events or otherwise, subject to its disclosure obligations under applicable rules promulgated by applicable Canadian provincial and territorial securities laws.
Article content
Article content
Article content
Article content
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
42 minutes ago
- Globe and Mail
Health Data Interoperability Market to Hit US$352.13 Billion by 2032 with 22.65% CAGR
According to a recent report by Coherent Market Insights, the global Health Data Interoperability Market is estimated to be valued at USD 84.58 billion in 2025 and is expected to reach USD 352.13 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 22.65% from 2025 to 2032. The strong growth of the market is driven by the rising demand for seamless data exchange among healthcare providers, the pursuit of enhanced patient care, and the growing adoption of electronic health records (EHRs) and other digital health technologies. Global Health Data Interoperability Market Key Takeaways According to Coherent Market Insights (CMI), the global health data operability care market size is projected to grow more than 4.1X, increasing from USD 84.58 Bn in 2025 to USD 352.13 Bn by 2032, at a CAGR of 22.65%. By deployment model, cloud-based segment is expected to account for nearly two-thirds of the global health data interoperability market share in 2025. Based on component, software category is anticipated to generate a market revenue of about USD 45.92 Bn in 2025. By type, electronic health records (EHRs) segment will likely account for more than two-fifths of the global market revenue share by 2025. North America is expected to retain its monopoly in the global market due to increasing adoption of digital health technologies. As per Coherent Market Insights' latest health data interoperability market research, North America will hold nearly 2/5 of the global market share in 2025. Asia Pacific health data interoperability market is estimated to be valued at around USD 25.62 Bn in 2025. Growing Adoption of Electronic Health Records (EHRs) Boosting Market Growth Coherent Market Insights' new health data interoperability market analysis offers insights into prominent factors driving industry growth. Increasing adoption of electronic health records (EHRs) is one key growth driver. In the contemporary world, more and more hospitals and clinics are embracing electronic health records. For instance, as per the National Center for Health Statistics, about 88.2% of office-based physicians in the United States use an EMR/EHR system. High adoption of EHRs is creating an urgent need for seamless data exchange across various healthcare systems. This will drive demand for health data interoperability solutions during the forecast period. High Implementation Cost and Lack of Standardization Limiting Market Growth The future health data interoperability market outlook looks promising. However, lack of universal standards and high implementation costs are expected to restrain market growth to some extent. Different healthcare providers often use disparate EHR systems, making seamless data exchange challenging. Absence of universally accepted interoperability standards across regions can hinder consistent integration and data sharing, negatively affecting the health data interoperability market growth. Implementing interoperable systems requires substantial investments in both infrastructure and software. This deters smaller clinics and healthcare providers, especially across underserved regions, from opting for these systems, thereby reducing the health data interoperability market demand. Purchase Now Up to 25% Discount on This Premium Research Report: Rapid Shift Towards Value-Based Care to Create Lucrative Growth Avenues Growing adoption of value-based care (VBC) models is driving demand for improved patient outcomes and cost efficiency across healthcare systems. This transition necessitates seamless health data interoperability to enable coordinated care as well as real-time data exchange and performance measurement. As a result, the shift towards VBC is unlocking significant growth opportunities for health data interoperability companies. Policies like HITECH Act and EU GDPR mandate interoperability as well as patient access to data. They will also create lucrative growth prospects for health data interoperability solution providers in the coming years. Policies like the HITECH Act and the EU GDPR emphasize interoperability as well as patient access to health data. These regulations are expected to drive demand for health data interoperability solutions, creating lucrative growth opportunities for industry players. Impact of AI on the Health Data Interoperability Market AI is revolutionizing the health data interoperability industry by tackling long-standing challenges like fragmented data and inconsistent data standards. Organizations use machine learning and NLP to automate data mapping, convert unstructured records into structured formats, and streamline EHR integration. AI-driven predictive analytics can forecast data exchange needs, enhance real‑time clinical workflows, and reduce clinical errors. Federated learning frameworks allow AI models to train across multiple organizations without moving sensitive patient data, which improves privacy and fosters collaboration. AI-powered interoperability solutions are gaining immense traction in the modern healthcare ecosystem. This is due to their potential to boost operational efficiency, enable personalized care, reduce costs, and accelerate the transition towards value‑based models. Emerging Health Data Interoperability Market Trends Rising demand for patient-centric care is a key growth-shaping trend in the market. Today, patients want access to their health information through mobile apps and patient portals. This is creating a need for connected systems. Growing popularity of cloud-based interoperability solutions is expected to boost the overall health data interoperability market value. These scalable and cost-effective platforms are gradually replacing on-premise systems across various regions. Rise of telehealth services and adoption of remote patient monitoring devices are also positively impacting the health data interoperability market growth. These technologies require robust interoperability solutions to ensure seamless data flow between patients, healthcare providers, and monitoring platforms. Analyst's View 'The global health data interoperability market is poised to exhibit robust growth, owing to increasing government mandates and regulatory frameworks, widespread adoption of electronic health and medical record systems (EHR/EMR), and a growing emphasis on value-based care models,' said senior analyst Komal Dighe. Current Events and Their Impact on the Health Data Interoperability Market Event Description and Impact U.S. HTI-1 Final Rule Description: U.S. HTI-1 Final Rule enforces FHIR-based standards for certified health IT systems. Impact: This drives adoption of compliant interoperability platforms and APIs, leading to market growth. EU's European Health Data Space (EHDS) Rollout Description: European Union's EHDS initiative, officially implemented in 2025, requires member states to adopt standardized cross-border health data sharing through unified interoperability frameworks. Impact: This is driving health IT vendors to comply with EHDS standards as well as boosting demand for FHIR-based platforms and multilingual data exchange solutions. Competitor Insights Key companies in health data interoperability market report include: - Cerner Corporation - Epic Systems Corporation - Meditech - Allscripts Healthcare Solutions - athenahealth - InterSystems Corporation - Philips Healthcare - GE Healthcare - Oracle Health Sciences - NextGen Healthcare - IBM Watson Health - Microsoft Health - McKesson Corporation - Siemens Healthineers - Infor Healthcare Key Developments In March 2025, 1upHealth sets a new benchmark for health data interoperability with the launch of its new 1up Platform. The new platform, built on a modern lakehouse architecture, is designed to deliver 'Health Data On Demand'. It offers real-time data access, scalable management, and advanced analytics to help healthcare organizations enhance operational efficiency, care quality, and patient outcomes. In March 2025, Epic Systems Corporation unveiled industry-leading Genomics, AI, and interoperability solutions at the HIMSS 2025 Conference. These new solutions are designed to help healthcare organizations advance in rapidly evolving environment. They have the potential to enhance clinical care, streamline operations, and foster more personalized patient treatments. In January 2025, MEDITECH unveiled its new set of APIs fully compatible with version 4 of the United States Core Data for Interoperability (USCDI v4). This new launch highlights the company's leadership in advancing standards-based interoperability across healthcare systems. Market Segmentation Deployment Model Insights Cloud-Based On-Premises Component Insights Hardware Software Services Type Insights Electronic Health Records (EHR) Health Information Exchange (HIE) Interoperability Solutions Integration Platforms Interoperability Level Insights Foundational Interoperability Structural Interoperability Semantic Interoperability End User Insights Healthcare Providers Healthcare Payers Pharmaceutical Companies Research Institutions Regional Insights North America U.S. Canada Latin America Brazil Argentina Mexico Rest of Latin America Europe Germany U.K. Spain France Italy Russia Rest of Europe Asia Pacific China India Japan Australia South Korea ASEAN Rest of Asia Pacific Middle East GCC Countries Israel Rest of Middle East Africa South Africa North Africa § Central Africa Get Customization on this Report: About Us: Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries. Media Contact Company Name: Coherent Market Insights Contact Person: Mr. Raj Shah Email: Send Email Phone: +1-252-477-1362 Address: 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States City: Burlingame State: California Country: United States Website:


Globe and Mail
an hour ago
- Globe and Mail
Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal
[content-module:CompanyOverview|NASDAQ:TSLA] When a stock climbs 14% in just two trading sessions despite getting hit with not one but two analyst downgrades, the market is sending a clear message. Tesla Inc (NASDAQ: TSLA) has done exactly that this week, shrugging off downgrades from both Baird and Argus Research as if they were minor speed bumps on a highway. For growth-focused investors, this apparent disconnect between Wall Street caution and actual market action represents something we love to see and write about: a buying opportunity. The Downgrades That Missed the Mark Monday brought a double dose of analyst pessimism when Baird cut Tesla from Buy to Hold, followed by Argus Research, who made the same move. Both firms cited the same primary concern: the very recent and very public spat between Elon Musk and President Trump, which they believe introduces significant uncertainty to Tesla's prospects. Baird's team also expressed particular skepticism about management's optimistic robotaxi timeline and suggested that positive expectations around the upcoming affordable vehicle launch, which we highlighted last week, might already be baked into the current share price. Meanwhile, Argus focused heavily on how the Musk-Trump dispute could weaken demand, especially as EV tax credits face potential expiration. They warned that Tesla's stock now appears driven more by non-fundamental events than actual business performance. Market Defiance Tells the Real Story But here's what makes Tesla so compelling as a stock to own: Tesla shares have actually gained 14% this week already, suggesting investors are treating the analyst caution as temporary noise rather than a very red warning sign. The stock's ability to climb despite fresh negative coverage indicates that the market sees through the political theater the underlying business momentum and long-term potential. After all, Tesla had posted what analysts called a fundamentally poor quarter in April, yet shares had already begun recovering before the Trump-Musk tensions erupted. That recovery trajectory appears to be reasserting itself regardless of Wall Street's newfound caution. The Bullish Chorus Remains Intact [content-module:Forecast|NASDAQ:TSLA] While Baird and Argus stepped to the sidelines, the broader analyst community tells a different story and is worth noting. The team at Piper Sandler actually reiterated their Overweight rating on Tuesday, echoing the updates from Morgan Stanley and Wedbush this month, already in maintaining bullish stances. Wedbush has been particularly aggressive, slapping a $500 price target on the stock and standing firm despite the recent volatility. This split in analyst opinion actually strengthens the contrarian case. When selective downgrades occur against a backdrop of maintained Buy ratings from other respected firms, it often signals that the negative factors are temporary rather than structural. Case in point: the fact that these downgrades focus primarily on political uncertainty rather than fundamental business deterioration supports this view. Perfect Storm for Patient Capital Tesla's current situation creates an almost textbook setup for contrarian investors. The stock has already absorbed a 25% hit from political noise, endured two high-profile downgrades, and still managed to surge 14% in just two sessions. This combination suggests that temporary headwinds are actually creating opportunity rather than risk. Consider this: if Tesla can gain 14% while dealing with two rare analyst downgrades and political uncertainty, imagine the potential upside once these temporary factors fade. The upcoming affordable vehicle launch and robotaxi development remain on track regardless of Washington drama, and Tesla's core EV market position continues to strengthen globally. For investors who believe in Tesla's long-term transformation story, the current moment offers something increasingly scarce: the chance to buy into a high-growth stock at a potential discount. The Window Is Already Narrowing All that being said, the market's quick dismissal of Monday's downgrades suggests this buying opportunity may be short-lived. Political tensions have a way of resolving themselves, especially when business interests are at stake. Meanwhile, Tesla's product roadmap and market expansion continue regardless of Twitter feuds or analyst hand-wringing. For investors willing to look past the headline noise, these rare downgrades may prove to be perfectly timed entry points rather than warning signals. Where Should You Invest $1,000 Right Now? Before you make your next trade, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list. They believe these five stocks are the five best companies for investors to buy now...


Globe and Mail
an hour ago
- Globe and Mail
Crude Prices Slip as Dollar Strength Sparks Long Liquidation
July WTI crude oil (CLN25) Tuesday closed down -0.31 (-0.47%), and July RBOB gasoline (RBN25) closed down -0.0072 (-0.34%). Crude oil and gasoline prices on Tuesday gave up an early advance and settled lower. Dollar strength (DXY00) on Tuesday sparked long liquidation pressures in crude oil, causing prices to retreat. Crude oil and gasoline initially moved higher Tuesday, with crude posting a 2-1/4 month high and gasoline posting a 2-week high. Signs of progress in US-China trade talks supported crude oil prices. Also, Tuesday's rally in the S&P 500 to a 3-1/2 month high shows confidence in the economic outlook that is supportive of energy demand and crude prices. The possibility of reduced trade tensions between the US and China is positive for economic growth and energy demand. US Commerce Secretary Lutnick said Tuesday that Monday's initial trade talks with China have been "fruitful." The trade negotiations continued Tuesday in London. Reduced oil production in Canada is bullish for crude prices, as wildfires in Alberta, Canada, have shut down nearly 350,000 barrels per day (bpd) of crude production, or approximately 7% of Canada's total output. The World Bank on Tuesday cut its 2025 global GDP forecast to +2.3% from a +2.7% estimate in January, which was negative for energy demand and crude prices. Crude prices were undercut last Wednesday after Bloomberg reported that Saudi Arabia is open to additional crude production hikes in a bid to increase its market share. The report stated that Saudi Arabia wants OPEC+ to increase crude output by 411,000 bpd in August and potentially in September to capitalize on peak summer demand. Signs of a global oil supply glut are weighing on crude prices, as crude oil inventories have risen by 170 million barrels over the past 100 days, according to Kayrros, which monitors inventories. An increase in crude oil held worldwide on tankers is bearish for oil prices. Vortexa reported Monday that crude oil stored on tankers that have been stationary for at least seven days rose by +9.1% w/w to 81.83 million bbl in the week ended June 6. Concern about a global oil glut is negative for crude prices. On May 31, OPEC+ agreed to a 411,000 bpd crude production hike for July after raising output by the same amount for June. Saudi Arabia has signaled that additional similar-sized increases in crude output could follow, which is viewed as a strategy to reduce oil prices and punish overproducing OPEC+ members, such as Kazakhstan and Iraq. OPEC+ is boosting output to reverse the 2-year-long production cut, gradually restoring a total of 2.2 million bpd of production. OPEC+ had previously planned to restore production between January and late 2025, but now that production cut won't be fully restored until September 2026. OPEC May crude production rose +200,000 bpd to 27.54 million bpd. Doubts about a nuclear deal between Iran and the US supported crude oil prices. Iranian Supreme Leader Ali Khamenei recently said that he doesn't think negotiations with the US will succeed, and he urged the Trump administration to stop "talking nonsense." President Trump recently said Iran will face "something bad" if it doesn't quickly accept a US proposal over its nuclear program. The consensus is that Wednesday's weekly EIA crude inventories will fall by -2.6 million, and gasoline supplies will climb by +750,000 bbl. Last Wednesday's EIA report showed that (1) US crude oil inventories as of May 30 were -7.0% below the seasonal 5-year average, (2) gasoline inventories were -1.6% below the seasonal 5-year average, and (3) distillate inventories were -17.2% below the 5-year seasonal average. US crude oil production in the week ending May 30 rose +0.1% w/w at 13.408 million bpd, modestly below the record high of 13.631 million bpd from the week of December 6. Baker Hughes reported last Friday that active US oil rigs in the week ending June 6 fell by -9 to a 3-1/2 year low of 442 rigs. The number of US oil rigs has fallen over the past two years from the 5-year high of 627 rigs posted in December 2022.